Connect with us

News

Sir Muir Gray: Doing it for ourselves is key to living longer and ageing better

Published

on

Professor Sir Muir Gray has said there needs to be a radical shift in the way healthcare is perceived if people are to live longer and better.

The public health and ageing expert has said governments and medical institutions like the NHS, need to focus more on disease prevention rather than just being seen as illness management specialists. 

Sharing his views on ageing better on the latest Agetech World podcast, Sir Muir has suggested that GPs and the NHS should start prescribing wellness rather than just drugs.

Click here to listen to the latest Agetech World podcast

But the 79-year-old former NHS Chief Knowledge Officer said it’s not just professional services that need to step up and engage more in preventative treatment.

The public is also responsible for taking care of their health by staying physically and mentally active if they want to remain well for longer, in their own home, and out of the hospital system.

Sir Muir, who is a professor in the Nuffield Department of Primary Health Care at the University of Oxford, and a director of the recently launched The Goldster Health Service (GHS) – an online health and wellness club pioneering a systematic non-drug approach to well-being to help deal with the challenges, aspirations, and triumphs of ageing – said being active lies at the heart of his philosophy.

Speaking about the NHS, Sir Muir, who is an internationally renowned authority on healthcare who has advised governments of several countries outside the UK, told the Agetech World podcast: “We need the NHS for three things. For diagnosis. Is it breast cancer, or is it a heart attack, or is it Parkinson’s; for acute care, when you can’t stand and you’re acutely unwell with pneumonia or whatever; and for starting the right treatment.

“So I had a stent put in. They started the treatment right, and they gave me three months attendance at a gym. This was 11 years ago.

“But in the last 11 years, I haven’t had a single word from the NHS about diet or exercise, although I have had a thousand boxes of pills. 

“So, what we are seeing now is that self-care is the most important type of care for prevention and for long-term condition management. 

“And that’s our mission at Goldster Health Service, to complement and supplement the NHS and to say if you guys can do the diagnosis, acute stay and starting treatment…then after the right treatment has been started it’s up to the citizen to take responsibility.

“I think we need to be much clearer with the public about what their role is and what the role of the NHS is.”

Professor Sir Muir Gray

He suggested a culture change is needed as the NHS has over the past few decades increasingly focused on drugs and technology and people have become more passive about their own health.

“Geriatric medicine’s been wonderful. The speciality of geriatric medicine is very, very important, and it changed the way the medical profession thought. So, we have to be clear what the problem is. 

“I have seen 20 reorganisations of the structure of the NHS, but actually structure is only one part of an organisation. You need systems; a system for living longer better, and then culture is even more important than structure.

“You have to be clear that we are trying to change culture.”

Some culture shifts have emerged in recent years, he argued. “It has certainly been very good that people are no longer denied treatment on the basis of their age, but what has happened is that the NHS assumes that every problem of an older person is due to some disease and requires clinical intervention.

“A result of this is what is called polypharmacy, people on numerous drugs. There is something called hyper-polypharmacy, where people have more than 10 drugs. 

“Now, drugs are very important. I’m on six drugs a day for my various heart and other health problems, and I value them highly, but a very large number of people in their 80s and 90s are on eight, or nine, or 10 drugs a day, and it is estimated that 10% of those drugs do no good.”

The NHS is this year marking its 75th anniversary. Founded in July 1948, it was the first free at the point of delivery, universal health system available to all. Currently the NHS treats over a million people each day in England alone. 

Whilst congratulating the NHS on the milestone, Sir Muir commented: “In 1948, the National Assistance Act, and the National Health Service Act, said that young disabled people….were to be given education to overcome their disabilities; the aged were to be given practical assistance. Don’t worry about it, just do things for them.

“But that is partly a failure to understand the biology of what is happening to us. So, our mission (at GHS) is a cultural revolution, really, as well as giving information to people, to support individuals. 

“We are clear we have to change what other people think, because, I think it was Sartre who said, ‘hell is other people,’; we have to change how other people think as well as changing how older people think.”

He continued: “Our job in Goldster is clearly cultural revolution. Supposing I was in Manchester, or Paris, or Gateshead, speaking to a group of either the public or professionals, I would tell them, ‘I am going to rewire your brains. You are thinking the wrong way.’

“We know that your brain can be rewired at any age. You sometimes see a man or a woman down at the end of the road in that big green box with telephone wires. It’s amazing how they join them together. That is what we are going to do to your brains.

“We are very clear that we are in the brain rewiring business. So, giving people knowledge, for example, saying that ageing by itself is not a cause of problems, major problems until the late-90s, that’s knowledge.”

 

News

Mole rat gene extends mouse lifespan

Published

on

A mole rat gene inserted into mice extended lifespan and improved health, findings that may point to new ways of supporting healthier ageing.

The gene increased production of a large form of hyaluronan, a naturally occurring gel-like substance between cells that helps tissue repair and cell-to-cell communication.

Mice carrying the naked mole rat version of the gene showed an approximately 4.4 per cent increase in median lifespan, alongside multiple markers of healthier ageing.

Naked mole rats have become a focus of ageing research because they combine an exceptional lifespan with unusual resistance to many age-linked diseases, including cancer.

Researchers at the University of Rochester traced part of that resilience to hyaluronan.

The molecule’s effects depend on its size: large forms are often linked to anti-inflammatory and tissue-protective behaviour, while smaller fragments can act as danger signals that increase inflammation.

Vera Gorbunova, professor of biology and medicine at the University of Rochester in the US, said: “Our study provides a proof of principle that unique longevity mechanisms that evolved in long-lived mammalian species can be exported to improve the lifespans of other mammals.”

The engineered mice were better protected against both spontaneous tumours and chemically induced skin cancer.

They also showed reduced inflammation across tissues, a notable finding because persistent low-grade inflammation, sometimes called inflammaging, is widely seen as one of the central drivers of age-related decline.

The research also linked the large form of hyaluronan to age-related gut health. As animals age, the gut barrier can become leakier, allowing inflammatory triggers to pass into the bloodstream.

The engineered mice showed protection against this deterioration.

Follow-up work found abundant high-molecular-mass hyaluronan across multiple species of subterranean mammals, often absent in closely related above-ground species, suggesting it may be part of a broader evolutionary toolkit for surviving long lives under harsh conditions.

The team said gene transfer is not the end goal. Gorbunova said: “It took us 10 years from the discovery of HMW-HA in the naked mole rat to showing that HMW-HA improves health in mice.”

“Our next goal is to transfer this benefit to humans.”

Two practical routes are being pursued: increasing production of the large form of hyaluronan, or slowing its breakdown.

Andrei Seluanov, who co-leads the research, said: “We already have identified molecules that slow down hyaluronan degradation and are testing them in pre-clinical trials.”

One candidate identified through screening is delphinidin, a plant pigment found in various fruits and vegetables.

In tests, it was found to increase levels of the large form of hyaluronan in cells and mouse tissues, reduce migration and invasion in multiple cancer cell lines, and suppress melanoma metastasis in mice.

However, the researchers acknowledged the approach has limits. A later study found that mice expressing the naked mole rat gene showed improvements in several late-life health measures but did not show protection from age-related hearing loss, suggesting some organs may be less reachable by this pathway than others.

The Rochester team said turning these findings into human therapies will likely depend on precision: maintaining the right molecular form of hyaluronan, targeting the right balance of production versus breakdown, and monitoring carefully for trade-offs as different tissues respond in different ways.

Continue Reading

News

AI can predict Alzheimer’s with almost 93% accuracy, researchers say

Published

on

Alzheimer’s AI can predict the disease with nearly 93 per cent accuracy using more than 800 brain scans, researchers say.

The system identified anatomical changes in the brain linked to the onset of the most common form of dementia, a condition that gradually damages memory and thinking.

The findings build on years of research suggesting AI could help spot early Alzheimer’s risk, predict disease and identify patients whose condition has not yet been diagnosed.

Benjamin Nephew, an assistant research professor at the Worcester Polytechnic Institute in Massachusetts, said: “Early diagnosis of Alzheimer’s disease can be difficult because symptoms can be mistaken for normal ageing.

“We found that machine-learning technologies, however, can analyse large amounts of data from scans to identify subtle changes and accurately predict Alzheimer’s disease and related cognitive states.”

The study used MRI scans, a type of detailed brain imaging, from 344 people aged 69 to 84.

The dataset included 281 scans showing normal mental function, 332 with mild cognitive impairment, an early stage of memory and thinking decline, and 202 with Alzheimer’s.

The scans covered 95 of the brain’s nearly 200 distinct regions and used an AI algorithm to predict patients’ health.

Being able to use AI to help diagnose Alzheimer’s earlier could give patients and doctors crucial time to prepare and potentially slow the progression of the disease.

The analysis showed that one of the top predictive factors was brain volume loss, or shrinkage, in the hippocampus, which helps form memories, the amygdala, which processes fear, and the entorhinal cortex, which helps provide a sense of time.

This pattern held across age and sex, with both men and women aged 69 to 76 showing volume loss in the right part of the hippocampus, suggesting it may be an important area for early diagnosis, the researchers noted.

However, the research also found that the way brain regions shrink differs by sex.

In females, volume loss occurred in the brain’s left middle temporal cortex, which is involved in language and visual perception. In males, it was mainly seen in the right entorhinal cortex

The researchers believe this could be linked to changes in sex hormones, including the loss of oestrogen in women and testosterone in men.

These conclusions could help improve methods of diagnosis and treatment going forward, Nephew said.

More than 7.2m Americans are living with Alzheimer’s, according to the Alzheimer’s Association.

More research is being done to reveal other impacting factors.

Nephew said: “The critical challenge in this research is to build a generalisable machine-learning model that captures the difference between healthy brains and brains from people with mild cognitive impairment or Alzheimer’s disease.”

Continue Reading

News

Vision implant firm raises US$230m

Published

on

A vision implant firm has raised US$230m as it seeks approval in Europe and the US for a device that restored sight in a small clinical trial.

The Alameda, California-based startup said the funding would support commercialisation of its Prima device.

It said an upcoming launch is planned in Europe and that it would become the first brain computer interface company to have a vision restoration device on the market.

A clinical trial in Europe found the small implant could work as artificial photoreceptors in the retina to restore functional central vision.

The implant is placed under the retina to replace the function of light-sensitive cells lost to disease. A special pair of glasses with an embedded camera and infrared projector sends light signals to the implant.

The study assessed the system in people with advanced dry age-related macular degeneration.

Of the 38 patients who received an implant, 32 were assessed at 12 months. Results showed the device led to a clinically meaningful improvement in visual acuity in 26 people.

The patients were able to read letters, numbers and words, according to the company.

Science Corporation said it has submitted a CE mark application to the European Union and applied to the US Food and Drug Administration for regulatory approval.

Darius Shahida, chief strategy officer, said: “Our imperative is to become the first BCI company to scale and achieve profitability.”

Founded in 2021, the company has now raised about US$490m in total. It said it is expanding its clinical trial programme to include other retinal diseases, such as Stargardt disease and retinitis pigmentosa.

The Series C round included existing investors Khosla Ventures, Lightspeed Venture Partners, Y Combinator, IQT and Quiet Capital.

Science Corporation said demand for the round exceeded its capital needs, with funds also earmarked for expanding research, manufacturing infrastructure and operations.

Continue Reading

Trending

Agetech World